Immunisation Weekly Update:

20190319 Immunisation Needle Icons 31

On 3 June, NSW Health distributed ​Mpox alert: Information for GPs which provides the following advice:

  • Local transmission of mpox has been reported in Victoria and Queensland
  • Encourage men who have sex with men (MSM) to have two doses of mpox vaccine to ensure they are fully vaccinated
  • Test for mpox in MSM with a compatible illness, even if fully vaccinated

Eligible vaccination providers can now report a medical contraindication for influenza vaccines to the AIR. This enhancement simplifies the reporting of medical contraindications for flu vaccines and reduces the burden of having to report multiple vaccine brands to the AIR.

Vaccination providers should only report a medical contraindication to the AIR for influenza vaccines if the individual is contraindicated to all flu vaccine brands.

Once the medical contraindication is recorded on the AIR, it will display on the individual’s AIR record, including their Immunisation History Statement. This enables individuals to generate accurate vaccination evidence to provide for school, employment and travel purposes.

Further information on how to report a medical contraindication to the AIR can be found on the Services Australia website.

The Australian Government Department of Health and Aged Care is seeking feedback from immunisation stakeholders and the general public to help inform Australia’s next National Immunisation Strategy, for the years 2025–2030.

The call for input follows the recent release of a public consultation paper, Towards a National Immunisation Strategy 2025–2030, that surveys the current immunisation landscape in Australia and proposes an approach for the strategy, including six identified priority areas.

Responses are to be sent via an online survey. Those wishing to provide feedback are encouraged to read the consultation paper before completing the survey.

The online survey deadline has been extended and will close at 11:59 p.m. (AEST) on Wednesday 19 June 2024.

RSV Awareness Week (2–8 June 2024) is an initiative of the Immunisation Foundation of Australia which seeks to increase awareness of respiratory syncytial virus (RSV) prevention, as well as emphasise the need to protect those most at risk of severe RSV-related illness. 

The past six months have seen significant progress via the approval of several new immunisation products for use in protecting infants and older adults from severe RSV disease and the introduction of the NSW Health RSV vulnerable babies program.

Professor Paul Kelly, Head of the interim Australian Centre for Disease Control (CDC), recently hosted a webinar for vaccination providers.  A recording of the webinar is now available.

In this webinar, ATAGI chair Professor Nigel Crawford discusses three respiratory viruses in the lead up to this year’s winter season: influenza, COVID-19, and respiratory syncytial virus (RSV). 

 

NSW Health released a statement strongly urging people aged 65 and over to get vaccinated as the latest NSW Health Respiratory Surveillance Report shows influenza activity is rapidly increasing in NSW.

The Immunisation Weekly Update will be including the latest NSW influenza vaccination coverage by age group each week. Practices are encouraged to recommend flu vaccination to all NIP eligible patients.

Age groupNSW coverage (as at 2 June 2024)
6 months to under 5 years15.8%
65 years and over50.9%